IL37,Tlymphocytes ,NK Cells in Pathogenesis of Immune Thrombocytopenia.
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 90
- 主要终点
- To decrease the immunity complications in ITP patients
研究概览
简要总结
To evaluate the role of IL37 in pathogenesis of ITP and to study the relation between IL37,Tlymphocytes,NK cells in ITP
详细描述
Idiopathic thrombocytopenia or immune thrombocytopenia (ITP) is a hematological condition which is characterized by a low platelet count of less than 100 x 109L . Symptoms of ITP can vary but tend to be symptoms of thrombocytopenia in general, such as petechiae, purpura, mucosal bleeding and in the most severe cases fatal intracranial hemorrhage(1,2) Interleukin (IL)-37, a novel anti-inflammatory cytokine previously known as interleukin-1 family member 7 before it was renamed, has a pivotal role in the suppression of immune responses (3,4). IL-37 is widely expressed in several types of cells, tissues and organs, including peripheral blood mononuclear cells (PBMCs) (5). The major role of IL-37 is to decrease excessive inflammation in innate and adaptive immune diseases, mainly by inhibiting the expression, production and function of pro-inflammatory cytokines, including IL-1α, IL-6, tumor necrosis factor (TNF) and macrophage inflammatory protein-2. The abundance of these cytokines has been reported to increase with the silencing of endogenous IL-37 in human blood cells (3,6).Aberrant expression of IL-37 has been observed in several inflammatory and autoimmune diseases However, the role of IL-37 in ITP has remained elusive. Immune thrombocytopenia pathogenesis is a complicated process. T cell immune abnormalities are involved in ITP pathogenesis. These abnormalities include platelet auto-antigen reactive cytotoxic T cells, abnormal numbers and functions of T regulatory cells, loss of Th1/Th2 balance, megakaryocyte maturation abnormalities and abnormal T cell anergy.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 2 Years 至 60 Years(Child, Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with ITP (moderate and sever) different age group.
排除标准
- •Patients with stroke and myocardial infarction,malignant tumors or pregnancy.
研究组 & 干预措施
ITP
Patient newly diagnosied with ITP
干预措施: Corticosteriod for treated patients (Drug)
Treated
Patients with ITP recived treatment
干预措施: Corticosteriod for treated patients (Drug)
Control
Healthy people
干预措施: Corticosteriod for treated patients (Drug)
结局指标
主要结局
To decrease the immunity complications in ITP patients
时间窗: Baseline
Early detection of immunity complications in ITP patients
To decrease case fatality rate
时间窗: Baseline
Early detection of immunity complication will decrease mortality rate
次要结局
未报告次要终点
研究者
Asmaa Mohamed Elsayed
Resident physician
Assiut University
